These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 2512447

  • 41. Synthesis of novel NBD-GM1 and NBD-GM2 for the transfer activity of GM2-activator protein by a FRET-based assay system.
    Schwarzmann G, Wendeler M, Sandhoff K.
    Glycobiology; 2005 Dec; 15(12):1302-11. PubMed ID: 16079415
    [Abstract] [Full Text] [Related]

  • 42. [Tay-Sachs disease].
    Itoh T, Miura AB.
    Ryoikibetsu Shokogun Shirizu; 1998 Dec; (22 Pt 3):389-92. PubMed ID: 9851170
    [No Abstract] [Full Text] [Related]

  • 43. Gangliosides containing glucosamine and galactosamine in transformed Tay-Sachs disease and normal human brain cell lines.
    Schneck L, Hoffman LM, Brooks SE, Amsterdam D.
    J Neurol Sci; 1980 Feb; 45(1):123-8. PubMed ID: 6244370
    [Abstract] [Full Text] [Related]

  • 44. CHROMATOGRAPHIC STUDIES OF NORMAL AND TAY-SACHS GANGLIOSIDES (PEPTIDE-STRANDIN).
    SAIFER A, ROBIN M, VOLK BW.
    J Neurochem; 1963 Aug; 10():577-86. PubMed ID: 14062003
    [No Abstract] [Full Text] [Related]

  • 45. A new variant of type-AB GM2-gangliosidosis.
    Li SC, Hirabayashi Y, Li YT.
    Biochem Biophys Res Commun; 1981 Jul 30; 101(2):479-85. PubMed ID: 7306091
    [No Abstract] [Full Text] [Related]

  • 46. Glycosphingolipids in fetal Tay-Sachs disease brain and lung cultures.
    Hoffman LM, Amsterdam D, Brooks SE, Schneck L.
    J Neurochem; 1977 Sep 30; 29(3):551-9. PubMed ID: 894310
    [No Abstract] [Full Text] [Related]

  • 47. Presence of an unusual GM2 derivative, taurine-conjugated GM2, in Tay-Sachs brain.
    Li YT, Maskos K, Chou CW, Cole RB, Li SC.
    J Biol Chem; 2003 Sep 12; 278(37):35286-91. PubMed ID: 12829702
    [Abstract] [Full Text] [Related]

  • 48. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin.
    Platt FM, Neises GR, Reinkensmeier G, Townsend MJ, Perry VH, Proia RL, Winchester B, Dwek RA, Butters TD.
    Science; 1997 Apr 18; 276(5311):428-31. PubMed ID: 9103204
    [Abstract] [Full Text] [Related]

  • 49. Assay of the GM2-ganglioside cleaving hexosaminidase activity of skin fibroblasts for GM2-gangliosidoses.
    Harzer K.
    Clin Chim Acta; 1983 Nov 30; 135(1):89-93. PubMed ID: 6228344
    [No Abstract] [Full Text] [Related]

  • 50. A sensitive fluorescence-based assay for monitoring GM2 ganglioside hydrolysis in live patient cells and their lysates.
    Tropak MB, Bukovac SW, Rigat BA, Yonekawa S, Wakarchuk W, Mahuran DJ.
    Glycobiology; 2010 Mar 30; 20(3):356-65. PubMed ID: 19917668
    [Abstract] [Full Text] [Related]

  • 51. Presentation of central precocious puberty in two patients with Tay-Sachs disease.
    Acar S, Arslan N, Paketçi A, Okur TD, Demir K, Böber E, Abacı A.
    Hormones (Athens); 2018 Sep 30; 17(3):415-418. PubMed ID: 29943104
    [Abstract] [Full Text] [Related]

  • 52. Apoptotic cell death in mouse models of GM2 gangliosidosis and observations on human Tay-Sachs and Sandhoff diseases.
    Huang JQ, Trasler JM, Igdoura S, Michaud J, Hanal N, Gravel RA.
    Hum Mol Genet; 1997 Oct 30; 6(11):1879-85. PubMed ID: 9302266
    [Abstract] [Full Text] [Related]

  • 53. Identification of the accumulated ganglioside.
    Svennerholm L.
    Adv Genet; 2001 Oct 30; 44():33-41. PubMed ID: 11596994
    [No Abstract] [Full Text] [Related]

  • 54. Enzyme replacement in Tay-Sachs disease.
    von Specht BU, Geiger B, Arnon R, Passwell J, Keren G, Goldman B, Padeh B.
    Neurology; 1979 Jun 30; 29(6):848-54. PubMed ID: 572006
    [Abstract] [Full Text] [Related]

  • 55. Immunochemical determination of ganglioside GM2, by inhibition of complement-dependent liposome lysis.
    Geiger B, Smolarsky M.
    J Immunol Methods; 1977 Jun 30; 17(1-2):7-19. PubMed ID: 333030
    [Abstract] [Full Text] [Related]

  • 56. A differential scanning calorimetry study of the interaction of gangliosides with peanut lectin, serotonin and daunomycin.
    Bach D, Sela BA.
    Biochim Biophys Acta; 1980 Feb 28; 596(2):186-91. PubMed ID: 7356996
    [Abstract] [Full Text] [Related]

  • 57. Enzyme replacement treatment for Tay-Sachs disease brain cells in culture utilizing concanavalin A-mediated hexosaminidase A uptake: biochemical and morphological evidence of GM2 mobilization.
    Brooks SE, Hoffman LM, Adachi M, Amsterdam D, Schneck L.
    Acta Neuropathol; 1980 Feb 28; 50(1):9-17. PubMed ID: 7376831
    [Abstract] [Full Text] [Related]

  • 58. [GM2-gangliodosis. A review of the biochemical genetic behavior].
    Nørby S.
    Ugeskr Laeger; 1979 Nov 19; 141(47):3222-6. PubMed ID: 392860
    [No Abstract] [Full Text] [Related]

  • 59. Late onset Tay-Sachs disease in mice with targeted disruption of the Hexa gene: behavioral changes and pathology of the central nervous system.
    Miklyaeva EI, Dong W, Bureau A, Fattahie R, Xu Y, Su M, Fick GH, Huang JQ, Igdoura S, Hanai N, Gravel RA.
    Brain Res; 2004 Mar 19; 1001(1-2):37-50. PubMed ID: 14972652
    [Abstract] [Full Text] [Related]

  • 60. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.
    Kitamura K, Livingston PO, Fortunato SR, Stockert E, Helling F, Ritter G, Oettgen HF, Old LJ.
    Proc Natl Acad Sci U S A; 1995 Mar 28; 92(7):2805-9. PubMed ID: 7708728
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.